This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (280)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Glaucoma  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

The Early Manifest Glaucoma Trial

M. Cristina Leske, MD, MPH; Anders Heijl, MD, PhD; Mohamed Hussein, PhD; Bo Bengtsson, MD, PhD; Leslie Hyman, PhD; Eugene Komaroff, PhD; for the Early Manifest Glaucoma Trial Group

Arch Ophthalmol. 2003;121:48-56.

Objective  To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment.

Setting/Participants  Two hundred fifty-five open-angle glaucoma patients randomized to argon laser trabeculoplasty plus topical betaxolol or no immediate treatment (129 treated; 126 controls) and followed up every 3 months.

Methods  Progression was determined by perimetric and photographic optic disc criteria. Patient-based risk of progression was evaluated using Cox proportional hazard regression models and was expressed as hazard ratios (HR) with 95% confidence intervals (95% CI).

Results  After 6 years, 53% of patients progressed. In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71). Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age. Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94). The first IOP at that visit (3 months' follow-up) was also related to progression (HR = 1.11 per millimeter of mercury higher; 95% CI, 1.06-1.17), as was the mean IOP at follow-up (HR = 1.13 per millimeter of mercury higher; 95% CI, 1.07-1.19). The percent of patient follow-up visits with disc hemorrhages was also related to progression (HR = 1.02 per percent higher; 95% CI, 1.01-1.03). No other factors were identified.

Conclusions  Patients treated in the EMGT had half of the progression risk of control patients. The magnitude of initial IOP reduction was a major factor influencing outcome. Progression was also increased with higher baseline IOP, exfoliation, bilateral disease, worse mean deviation, and older age, as well as frequent disc hemorrhages during follow-up. Each higher (or lower) millimeter of mercury of IOP on follow-up was associated with an approximate 10% increased (or decreased) risk of progression.

From the Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, NY (Drs Leske, Hussein, Hyman, and Komaroff); and the Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden (Drs Heijl and Bengtsson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Central Corneal Thickness and Optic Disc Hemorrhages: The Beijing Eye Study
Liang Xu, Haitao Zhang, Ya Xing Wang, and Jost B. Jonas
Arch Ophthalmol. 2008;126(3):435-436.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Blood pressure and glaucoma
Costa et al.
Br J Ophthalmol 2009;93:1276-1282.
ABSTRACT | FULL TEXT  

Glaucoma With Early Visual Field Loss Affecting Both Hemifields and the Risk of Disease Progression
De Moraes et al.
Arch Ophthalmol 2009;127:1129-1134.
ABSTRACT | FULL TEXT  

Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population
Nakano et al.
Proc. Natl. Acad. Sci. USA 2009;106:12838-12842.
ABSTRACT | FULL TEXT  

Advances in telemetric continuous intraocular pressure assessment
Kakaday et al.
Br J Ophthalmol 2009;93:992-996.
ABSTRACT | FULL TEXT  

Nipradilol and Timolol Induce Foxo3a and Peroxiredoxin 2 Expression and Protect Trabecular Meshwork Cells from Oxidative Stress
Miyamoto et al.
IOVS 2009;50:2777-2784.
ABSTRACT | FULL TEXT  

The Circadian Curve of Intraocular Pressure: Can We Estimate Its Characteristics during Office Hours?
Fogagnolo et al.
IOVS 2009;50:2209-2215.
ABSTRACT | FULL TEXT  

Genetic Risk for Primary Open-Angle Glaucoma Determined by LMX1B Haplotypes
Park et al.
IOVS 2009;50:1522-1530.
ABSTRACT | FULL TEXT  

Detection of Progressive Retinal Nerve Fiber Layer Loss in Glaucoma Using Scanning Laser Polarimetry with Variable Corneal Compensation
Medeiros et al.
IOVS 2009;50:1675-1681.
ABSTRACT | FULL TEXT  

Femtosecond Laser Photodisruption of Primate Trabecular Meshwork: An Ex Vivo Study
Nakamura et al.
IOVS 2009;50:1198-1204.
ABSTRACT | FULL TEXT  

Comparison of Risk Factors for Bilateral and Unilateral Eye Involvement in Normal-Tension Glaucoma
Kim and Kim
IOVS 2009;50:1215-1220.
ABSTRACT | FULL TEXT  

Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials
Honrubia et al.
Br J Ophthalmol 2009;93:316-321.
ABSTRACT | FULL TEXT  

Screening Tests for Detecting Open-Angle Glaucoma: Systematic Review and Meta-analysis
Mowatt et al.
IOVS 2008;49:5373-5385.
ABSTRACT | FULL TEXT  

Predictors of and Barriers Associated With Poor Follow-up in Patients With Glaucoma in South India
Lee et al.
Arch Ophthalmol 2008;126:1448-1454.
ABSTRACT | FULL TEXT  

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4
Williams et al.
Br J Ophthalmol 2008;92:1387-1392.
ABSTRACT | FULL TEXT  

Canadian Glaucoma Study: 2. Risk Factors for the Progression of Open-angle Glaucoma
Chauhan et al.
Arch Ophthalmol 2008;126:1030-1036.
ABSTRACT | FULL TEXT  

Exfoliation Syndrome: Beyond Glaucoma
Ritch
Arch Ophthalmol 2008;126:859-861.
FULL TEXT  

Caffeine Consumption and the Risk of Primary Open-Angle Glaucoma: A Prospective Cohort Study
Kang et al.
IOVS 2008;49:1924-1931.
ABSTRACT | FULL TEXT  

Effectiveness and Safety of Dorzolamide-Timolol Alone or Combined with Latanoprost in Open-Angle Glaucoma or Ocular Hypertension
Lesk et al.
The Annals of Pharmacotherapy 2008;42:498-504.
ABSTRACT | FULL TEXT  

Central Corneal Thickness and Optic Disc Hemorrhages: The Beijing Eye Study
Xu et al.
Arch Ophthalmol 2008;126:435-436.
FULL TEXT  

Estimating the Rate of Progressive Visual Field Damage in Those with Open-Angle Glaucoma, from Cross-Sectional Data
Broman et al.
IOVS 2008;49:66-76.
ABSTRACT | FULL TEXT  

Novel pressure-to-cornea index in glaucoma
Iliev et al.
Br J Ophthalmol 2007;91:1364-1368.
ABSTRACT | FULL TEXT  

Genome-Wide Scan of Exfoliation Syndrome
Lemmela et al.
IOVS 2007;48:4136-4142.
ABSTRACT | FULL TEXT  

The amount of intraocular pressure rise during pharmacological pupillary dilatation is an indicator of the likelihood of future progression of glaucoma
Siam et al.
Br J Ophthalmol 2007;91:1170-1172.
ABSTRACT | FULL TEXT  

Long-term Intraocular Pressure Fluctuation and Progressive Visual Field Deterioration in Patients With Glaucoma and Low Intraocular Pressures After a Triple Procedure
Hong et al.
Arch Ophthalmol 2007;125:1010-1013.
ABSTRACT | FULL TEXT  

Effects of Topical Administration of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Ocular Tissues in Rabbits and Monkeys
Tokushige et al.
IOVS 2007;48:3216-3222.
ABSTRACT | FULL TEXT  

Retinal vein pulsation predicts increasing optic disc excavation
Nicolela
Br J Ophthalmol 2007;91:405-406.
FULL TEXT  

Bone Morphogenetic Protein-7 Is an Antagonist of Transforming Growth Factor-{beta}2 in Human Trabecular Meshwork Cells
Fuchshofer et al.
IOVS 2007;48:715-726.
ABSTRACT | FULL TEXT  

Evaluation of the beta2-Adrenergic Receptor Gene as a Candidate Glaucoma Gene in 2 Ancestral Populations
McLaren et al.
Arch Ophthalmol 2007;125:105-111.
ABSTRACT | FULL TEXT  

Comparison of the Stability, Efficacy, and Adverse Effect Profile of the Innovator 0.005% Latanoprost Ophthalmic Solution and a Novel Cyclodextrin-containing Formulation
Gonzalez et al.
J Clin Pharmacol 2007;47:121-126.
ABSTRACT | FULL TEXT  

Microprocessor controlled compliance monitor for eye drop medication
Hermann and Diestelhorst
Br J Ophthalmol 2006;90:830-832.
ABSTRACT | FULL TEXT  

Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma.
Barkana et al.
Arch Ophthalmol 2006;124:793-797.
ABSTRACT | FULL TEXT  

Longitudinal changes in central corneal thickness and their relation to glaucoma status: an 8 year follow up study
Weizer et al.
Br J Ophthalmol 2006;90:732-736.
ABSTRACT | FULL TEXT  

Effect of moderate intraocular pressure changes on topographic measurements with confocal scanning laser tomography in patients with glaucoma.
Nicolela et al.
Arch Ophthalmol 2006;124:633-640.
ABSTRACT | FULL TEXT  

The future of glaucoma clinics
Morley and Murdoch
Br J Ophthalmol 2006;90:640-645.
ABSTRACT | FULL TEXT  

Detection of psychophysical and structural injury in eyes with glaucomatous optic neuropathy and normal standard automated perimetry.
Bagga et al.
Arch Ophthalmol 2006;124:169-176.
ABSTRACT | FULL TEXT  

The rising cost of glaucoma drugs
Azuara-Blanco and Burr
Br J Ophthalmol 2006;90:130-131.
FULL TEXT  

A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated With Severity of Disease in Glaucoma
Lee et al.
Arch Ophthalmol 2006;124:12-19.
ABSTRACT | FULL TEXT  

Anterior Optic Nerve Capillary Blood Flow Response to Diurnal Variation of Mean Ocular Perfusion Pressure in Early Untreated Primary Open-Angle Glaucoma
Sehi et al.
IOVS 2005;46:4581-4587.
ABSTRACT | FULL TEXT  

Regulation of Glucocorticoid Responsiveness in Glaucomatous Trabecular Meshwork Cells by Glucocorticoid Receptor-{beta}
Zhang et al.
IOVS 2005;46:4607-4616.
ABSTRACT | FULL TEXT  

Trypan blue staining of antiproliferative agents for trabeculectomy surgery and bleb needling
Franks
Br J Ophthalmol 2005;89:1394-1395.
FULL TEXT  

Unsupervised Machine Learning with Independent Component Analysis to Identify Areas of Progression in Glaucomatous Visual Fields
Sample et al.
IOVS 2005;46:3684-3692.
ABSTRACT | FULL TEXT  

Comparative Study of Retinal Nerve Fiber Layer Measurement by StratusOCT and GDx VCC, II: Structure/Function Regression Analysis in Glaucoma
Leung et al.
IOVS 2005;46:3702-3711.
ABSTRACT | FULL TEXT  

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe
Traverso et al.
Br J Ophthalmol 2005;89:1245-1249.
ABSTRACT | FULL TEXT  

The relation between intraocular pressure peak in the water drinking test and visual field progression in glaucoma
Susanna et al.
Br J Ophthalmol 2005;89:1298-1301.
ABSTRACT | FULL TEXT  

Central corneal thickness and progression of the visual field and optic disc in glaucoma
Chauhan et al.
Br J Ophthalmol 2005;89:1008-1012.
ABSTRACT | FULL TEXT  

Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials
Maier et al.
BMJ 2005;331:134.
ABSTRACT | FULL TEXT  

Twenty-four-Hour Control With Latanoprost-Timolol-Fixed Combination Therapy vs Latanoprost Therapy
Konstas et al.
Arch Ophthalmol 2005;123:898-902.
ABSTRACT | FULL TEXT  

Intraocular pressure variability in patients who reached target intraocular pressure
Malerbi et al.
Br J Ophthalmol 2005;89:540-542.
ABSTRACT | FULL TEXT  

Glaucoma and its treatment: A review
Lee and Higginbotham
Am J Health Syst Pharm 2005;62:691-699.
ABSTRACT | FULL TEXT  

Central Corneal Thickness and Thickness of the Lamina Cribrosa in Human Eyes
Jonas and Holbach
IOVS 2005;46:1275-1279.
ABSTRACT | FULL TEXT  

The Gradient of Retinal Functional Changes during Acute Intraocular Pressure Elevation
Bui et al.
IOVS 2005;46:202-213.
ABSTRACT | FULL TEXT  

Overexpression and Properties of Wild-Type and Tyr437His Mutated Myocilin in the Eyes of Transgenic Mice
Zillig et al.
IOVS 2005;46:223-234.
ABSTRACT | FULL TEXT  

Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom
Zhou et al.
Br J Ophthalmol 2004;88:1391-1394.
ABSTRACT | FULL TEXT  

Clinical Significance of Central Corneal Thickness in the Management of Glaucoma
Shih et al.
Arch Ophthalmol 2004;122:1270-1275.
ABSTRACT | FULL TEXT  

A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe
Garcia-Sanchez et al.
Br J Ophthalmol 2004;88:877-883.
ABSTRACT | FULL TEXT  

Prospective case control study on genetic assocation of apolipoprotein {varepsilon}2 with intraocular pressure
Junemann et al.
Br J Ophthalmol 2004;88:581-582.
FULL TEXT  

Does Sex Matter in Glaucoma?
Higginbotham
Arch Ophthalmol 2004;122:374-375.
FULL TEXT  

'This added to my multiple myopia'
Irwig
BMJ 2003;326:1336-1336.
FULL TEXT